Adaptin Bio (APTN) Cash from Operations (2023 - 2026)
Adaptin Bio's (APTN) quarterly Cash from Operations came in at -$450164.0 in Q2 2026, up 55.98% year-over-year from -$288597.7 in Q2 2025, and up 24.51% quarter-over-quarter from -$596298.0 in Q1 2026.
Powered by 
Analysis
Adaptin Bio (APTN) Cash from Operations (2023 - 2026) Analysis & Trends
Adaptin Bio has disclosed Cash from Operations across 4 years of filings, most recently posting -$450164.0 for Q2 2026.
- In Q2 2026, Cash from Operations rose 55.98% year-over-year to -$450164.0; the TTM figure through Jun 2026 stood at -$2.5 million (up 31.07% YoY), while the FY2025 annual figure was -$4.8 million, down 635.87% from the prior year.
- Cash from Operations came in at -$450164.0 for Q2 2026 at Adaptin Bio, up from -$596298.0 in the prior quarter.
- In the past five years, Cash from Operations ranged from a high of $112653.0 in Q4 2024 to a low of -$2.3 million in Q1 2025.
- Average Cash from Operations over 4 years is -$593816.7, with a median of -$468416.0 recorded in 2024.
- Year-over-year, Cash from Operations soared 293.07% in 2024 and slumped 2441.81% in 2025.
- Over 4 years, Cash from Operations stood at -$58347.0 in 2023, then soared by 293.07% to $112653.0 in 2024, then slumped by 723.93% to -$702876.0 in 2025, then surged by 35.95% to -$450164.0 in 2026.
- Per Business Quant data, the three most recent Cash from Operations figures were -$450164.0 in Q2 2026, -$596298.0 in Q1 2026, and -$702876.0 in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Krystal Biotech | 10.27 Bn | 9.43 Bn | 112.79 Mn | 74.79 Mn |
| 2 | CRISPR Therapeutics AG | 5.17 Bn | 5.17 Bn | - | -83.50 Mn |
| 3 | Iovance Biotherapeutics | 3.79 Bn | 3.49 Bn | 55.72 Mn | -60.82 Mn |
| 4 | Legend Biotech | 3.68 Bn | 2.71 Bn | 251.50 Mn | -20.90 Mn |
| 5 | uniQure | 3.05 Bn | 3.05 Bn | 5.49 Mn | -28.58 Mn |
| 6 | Beam Therapeutics | 2.65 Bn | 2.65 Bn | - | -66.10 Mn |
| 7 | Precigen | 2.44 Bn | 2.44 Bn | 52.17 Mn | -17.81 Mn |
| 8 | Sarepta Therapeutics | 2.33 Bn | 1.53 Bn | 251.87 Mn | 197.07 Mn |
| 9 | Vericel | 1.99 Bn | 1.83 Bn | 56.40 Mn | 16.19 Mn |
| 10 | Adaptin Bio | 56.76 Mn | 56.09 Mn | - | -450,164.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -450,164.00 |
| Mar 31, 2026 | -596,298.00 |
| Dec 31, 2025 | -702,876.00 |
| Sep 30, 2025 | -772,430.00 |
| Jun 30, 2025 | -1.02 Mn |
| Mar 31, 2025 | -2.28 Mn |
| Dec 31, 2024 | 112,653.00 |
| Sep 30, 2024 | -468,416.00 |
| Jun 30, 2024 | -203,825.00 |
| Mar 31, 2024 | -89,695.00 |
| Dec 31, 2023 | -58,347.00 |